Does Creatine Cause Hair Loss? The DHT Story Meets a Direct Trial

Itemized, the case against creatine contains: one 2009 trial, college-aged rugby players, a loading phase, a maintenance phase, a measured rise in dihydrotestosterone. It does not contain: a counted hair, a photographed scalp, a follicle of any kind. The legend that swept fitness culture—take creatine, raise DHT, lose hair—was built from the first list and repeated as if it included the second.

Itemized, the later record contains a 2025 randomized controlled trial: twelve weeks, hormones measured, follicles measured directly, no significant evidence that creatine worsened hair density or related measures. What no inventory can yet contain is certainty about years of use in every genetically susceptible subgroup.

The question matters because creatine is among the most-studied supplements in sports and the warning is among the most repeated. The most defensible current answer: the hair-loss claim was inferred from a hormone, not observed in hair, and the one trial that looked directly found no significant harm—though twelve weeks cannot rule out very long-term effects.

Where the claim comes from

A 2009 trial in rugby players reported increased dihydrotestosterone, or DHT, after a creatine loading phase and maintenance. DHT is involved in androgenetic alopecia in susceptible follicles, so the result supplied a plausible bridge from supplement to hair loss. The study was small, the hormone finding was not a hair endpoint, and it was not consistently replicated.

What the strongest human evidence shows

A 2025 randomized controlled trial directly assessed hair outcomes during 12 weeks of creatine supplementation. Investigators measured hormones and follicular measures rather than inferring hair loss from DHT alone. They found no significant between-group evidence that creatine worsened hair density or related hair parameters over the study period.

The newer trial answers the claim more directly, but 12 weeks cannot exclude a small effect over years or in every genetically susceptible subgroup. Broader creatine safety reviews find extensive evidence for performance and training support with no established alopecia signal, while spontaneous anecdotes remain unable to separate age-related onset, genetics, stress, weight change, or other products.

The evidence moves at different speeds. Mechanisms sprint ahead with possibility. Small trials test a dose and an endpoint. Cohorts follow patterns over years. None crosses the finish line marked “longer life” alone.

What the headline leaves out

A null trial does not prove zero risk under every dose and duration. Hair growth cycles are long, androgenetic alopecia progresses gradually, and the participants may not represent people at highest inherited risk. Conversely, a temporary hormone change cannot prove follicular miniaturization without direct hair outcomes.

Then come the brakes: confounding, reverse causation, selection, measurement error, short follow-up, small samples. Reviews can gather the studies into one place, but they cannot turn weak inputs into a strong conclusion by stacking them higher.

Why the claim spreads so well

The claim links a visible, feared outcome to a familiar hormone and a single memorable study. Hair loss commonly begins during the same years that people start training supplements, making temporal coincidence easy to interpret as causation. Online repetition then gives the original signal more weight than its design supports.

An evidence-first way to use the information

Creatine users concerned about hair can document baseline photographs under consistent lighting and discuss progressive shedding with a clinician rather than relying on day-to-day impressions. Stopping and restarting supplements can generate noisy anecdotes. The best current evidence is reassuring but not a lifetime guarantee.

The body—not the headline—absorbs the cost, burden, and risk. Low-risk experimentation is not equivalent to escalating a dose, abandoning established care, or paying for an invasive protocol whose promised outcome was never tested.

Strip the claim to its moving parts: population, dose, comparator, endpoint, duration. Did the study change something clinically meaningful, or merely a number that points in an interesting direction?

The verdict

Creatine has not been shown to cause hair loss. The original concern came from a small DHT study without hair measurements, and the first direct randomized hair trial found no significant adverse effect over 12 weeks.

Science can reverse this verdict, but it must do the work: adequate power, independent replication, characterized interventions, meaningful outcomes, and harms counted with the same enthusiasm as benefits. Educational, not medical advice.